These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 19749420

  • 21. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP.
    Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
    [Abstract] [Full Text] [Related]

  • 22. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K.
    J Alzheimers Dis; 2010 Mar; 22(4):1281-8. PubMed ID: 20930282
    [Abstract] [Full Text] [Related]

  • 23. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [Abstract] [Full Text] [Related]

  • 24. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D.
    J Neural Transm Suppl; 1998 Dec; 53():209-21. PubMed ID: 9700659
    [Abstract] [Full Text] [Related]

  • 25. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
    Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E.
    Mov Disord; 2009 Nov 15; 24(15):2203-10. PubMed ID: 19795497
    [Abstract] [Full Text] [Related]

  • 26. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun 15; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 27. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2009 Jun 15; 28(1):88-94. PubMed ID: 19672066
    [Abstract] [Full Text] [Related]

  • 28. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M.
    Ann Neurol; 1998 Jul 15; 44(1):17-26. PubMed ID: 9667589
    [Abstract] [Full Text] [Related]

  • 29. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
    Neurology; 2009 Oct 27; 73(17):1353-8. PubMed ID: 19858456
    [Abstract] [Full Text] [Related]

  • 30. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.
    Neurobiol Aging; 2009 Feb 27; 30(2):165-73. PubMed ID: 17646035
    [Abstract] [Full Text] [Related]

  • 31. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
    Brandt C, Bahl JC, Heegaard NH, Waldemar G, Johannsen P.
    Dement Geriatr Cogn Disord; 2008 Feb 27; 25(6):553-8. PubMed ID: 18536519
    [Abstract] [Full Text] [Related]

  • 32. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
    Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter-Jönhagen M.
    Neurobiol Aging; 2008 Oct 27; 29(10):1466-73. PubMed ID: 17512092
    [Abstract] [Full Text] [Related]

  • 33. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
    Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A, Federici G, Bernardi G, Sancesario G.
    Exp Neurol; 2010 Jun 27; 223(2):371-6. PubMed ID: 19664624
    [Abstract] [Full Text] [Related]

  • 34. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 27; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 35. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L.
    Funct Neurol; 2008 Feb 27; 23(2):93-6. PubMed ID: 18671910
    [Abstract] [Full Text] [Related]

  • 36. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Feb 27; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 37. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
    Fellgiebel A, Kojro E, Müller MJ, Scheurich A, Schmidt LG, Fahrenholz F.
    J Geriatr Psychiatry Neurol; 2009 Mar 27; 22(1):3-9. PubMed ID: 19073834
    [Abstract] [Full Text] [Related]

  • 38. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec 27; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

  • 39. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.
    Arch Neurol; 2010 Feb 27; 67(2):217-23. PubMed ID: 20142530
    [Abstract] [Full Text] [Related]

  • 40. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
    Sáez-Valero J, Fodero LR, Sjögren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH.
    J Neurosci Res; 2003 May 15; 72(4):520-6. PubMed ID: 12704813
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.